重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 15 日 (二)股东大会召开的地点：公司（武汉市东西湖区金山大道 1310 号）A 栋 A 会议 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 789 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 43,839,503 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 21.2618 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 证券代码：603716 证券简称：塞力医疗 公告编号：2025-078 塞力斯医疗科技集团股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次股东大会由塞力斯医疗科技集团股份有限公司董事会召集，由公司董事 长温伟先生主持。本次会议的召集、召开、表决方 ...

国浩律师（上海）事务所 国浩律师（上海）事务所 之 法律意见书 上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28th Floor, Suhe Centre, No.99 West Shanxi Road, Shanghai 200085, China 电话/Tel:+86 21 5234 1668 传真/Fax:+86 21 5243 3320 网址/Website: http://www.grandall.com.cn 2025 年 9 月 国浩律师（上海）事务所 法律意见书 关 于 塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会 关于塞力斯医疗科技集团股份有限公司 2025 年第四次临时股东大会之法律意见书 致：塞力斯医疗科技集团股份有限公司 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2025 年第四次临 时股东大会于 2025 年 9 月 15 日召开。国浩律师（上海）事务所（以下简称 "本所"）经公司聘请，委派律师出席现场会议，见证公司 2025 年第四次临时 股东大会（以下简称"本次股东大会"）。 本所律师根据《中华人民共和国公司法》《 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.14% on September 15, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index rose by 0.63% to 13005.77 [1] Stock Performance - Notable gainers in the pharmaceutical sector included Baiyang Pharmaceutical, which rose by 1.37% to a closing price of 31.06, and HeFu China, which increased by 1.04% to 6.80 [1] - Saily Medical saw a significant decline of 3.96%, closing at 30.07, with a trading volume of 423,500 shares and a transaction value of 1.287 billion [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 338 million from major funds, while retail investors contributed a net inflow of 265 million [2][3] - The stock with the highest net inflow from major funds was Yifeng Pharmacy, with 25.68 million, while it faced a net outflow of 21.63 million from retail investors [3]

Core Viewpoint - The announcement details the pledge of shares by the controlling shareholder of Saily Medical Technology Group Co., Ltd., indicating a significant portion of shares has been pledged, but the company maintains that this will not affect its operations or control [2][5][6]. Group 1: Share Pledge Details - The controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, representing 10.30% of the total share capital, and has pledged 3,000,000 shares recently [2]. - After the recent pledge, Saihai Technology has a total of 17,000,000 pledged shares, which is 78.55% of its holdings and 8.09% of the total share capital [2]. - The actual controller, Mr. Wen Wei, holds 9,634,208 shares (4.58% of total share capital) and has pledged 5,300,000 shares, which is 55.01% of his holdings [2]. Group 2: Future Pledge and Financing - Within the next six months, 6,000,000 shares are set to mature, accounting for 19.18% of their holdings and 2.86% of total share capital, with a corresponding financing balance of 14.61 million yuan [5]. - In the next year, an additional 9,000,000 shares will mature, representing 28.78% of their holdings and 4.28% of total share capital, with a financing balance of 36 million yuan [5]. - The funds from the recent pledge are primarily intended to repay previous pledge financing debts, and the company asserts that it has the ability to repay these debts [5][6]. Group 3: Risk Management and Impact - The company states that the pledge will not impact its operations, main business, financing costs, or ongoing viability, and there is no risk of a change in actual control [6]. - The credit status of Saihai Technology and Mr. Wen Wei is reported to be good, with manageable pledge risks, and they are prepared to take measures if stock prices approach warning or liquidation levels [6].

Group 1 - The company, Saily Medical, announced that its controlling shareholder, Saihai Technology, has pledged 3 million shares, bringing the total pledged shares to 17 million, which is 78.55% of Saihai's holdings and 8.09% of the total shares outstanding [1] - The actual controller, Mr. Wen Wei, holds approximately 9.63 million shares, representing 4.58% of the total shares, and has pledged 530,000 shares, which is 55.01% of his holdings and 2.52% of the total shares [1] - As of the announcement date, the total pledged shares by Saihai Technology and Mr. Wen Wei amount to 22.3 million, accounting for 71.3% of their combined holdings and 10.61% of the total shares outstanding [1] Group 2 - For the fiscal year 2024, Saily Medical's revenue composition is projected to be 97.09% from commercial activities and 2.91% from industrial activities [1] - The company's market capitalization is currently valued at 6.6 billion yuan [2]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-077 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 10.30%（截至 2025 年 8 月 20 日总股 本，下同）。近日，赛海科技将其中 3,000,000 股股份办理了质押登记手续。本 次质押手续办理完毕后，赛海科技累计质押公司股份 17,000,000 股，占其持有 公司股份比例为 78.55%，占公司总股本比例为 8.09%。 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 4.58%。温伟先生累计质押公司股份 5,300,000 股，占其持 ...

Market Overview - On September 12, the pharmaceutical commercial sector declined by 0.51%, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3883.69, up 0.22%, while the Shenzhen Component Index closed at 12996.38, up 0.13% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) leading with a 10.01% increase, closing at 31.31 [1] - Other notable performers included Haiwang Biological (000078) with a 2.69% increase and Runda Medical (603108) with a 1.30% increase [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 295 million yuan from institutional investors, while retail investors experienced a net outflow of 113 million yuan [2] - Major stocks like Seer Medical had a significant net inflow of 5.15 billion yuan from institutional investors, while retail investors showed a net outflow of 2.61 billion yuan [2]

Group 1 - The innovative drug concept stocks are showing strength, with Seer Medical hitting the daily limit up [1] - Guangsheng Tang increased by over 7%, indicating positive market sentiment [1] - Other companies such as Yuandong Biological, Huahai Pharmaceutical, Zhaoyan New Drug, and Enhua Pharmaceutical also experienced upward movement [1]

Group 1 - The core viewpoint of the news is that Sely Medical's stock has increased by 5.02%, reaching a price of 29.89 yuan per share, with a trading volume of 3.09 billion yuan and a turnover rate of 5.02%, resulting in a total market capitalization of 62.81 billion yuan [1] - Sely Medical Technology Group Co., Ltd. is located in Wuhan, Hubei Province, and was established on February 23, 2004, with its listing date on October 31, 2016. The company's main business includes centralized marketing and service for medical testing, agency for in vitro diagnostic products, and research, production, and sales of self-developed in vitro diagnostic products [1] - The revenue composition of Sely Medical's main business is as follows: IVD business accounts for 39.91%, SPD business accounts for 38.01%, and pure sales account for 22.08% [1] Group 2 - From the perspective of Sely Medical's top ten circulating shareholders, a fund under Caitong Fund ranks among the top shareholders. Caitong Advantage Industry Rotation Mixed A (011201) entered the top ten circulating shareholders in the second quarter, holding 643,400 shares, which accounts for 0.34% of the circulating shares. The estimated floating profit today is approximately 920,100 yuan [2] - Caitong Advantage Industry Rotation Mixed A (011201) was established on February 9, 2021, with a latest scale of 536 million yuan. Year-to-date return is 27.92%, ranking 2916 out of 8174 in its category; the one-year return is 47.03%, ranking 3325 out of 7981; and since inception, it has a loss of 22.16% [2]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]